B-1250 Waverley Street
102 articles with DiaMedica Inc.
DiaMedica Therapeutics to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4 th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform. DiaMedica Therapeutics management is scheduled to meet with investor
DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, announced positive top-line results from ReMEDy, its Phase II study in acute ischemic stroke, as well as provided a business update and financial results for the three months ended March 31, 2020.
DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study
Company to discuss top-line data during its scheduled first quarter financial results conference call tomorrow at 8:00 am Eastern Time
DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled “Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease” at the National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference. For information about the virtual event, visit:
DiaMedica Therapeutics to Report Fourth Quarter 2019 Financials and Provide a Business Update March 24, 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its fourth quarter 2019 financial results will be released after the markets close on Monday, March 23 rd . DiaMedica will host a live conference call on Tuesday, March 24 th at 7:00 AM Central Time to discuss its business update and financial results. Conference Call details: Date: Tuesday, March 24, 2020 Time:
DiaMedica Therapeutics Inc. announced the closing of its previously announced underwritten public offering of an aggregate of 2,125,000 shares of its voting common shares at a public offering price of $4.00 per share.
DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
DiaMedica Therapeutics Inc. announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease.
DiaMedica Therapeutics Inc. provided a business update and reported its financial results for the three and nine months ended September 30, 2019.
DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019
DiaMedica Therapeutics Inc. announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13th.
DiaMedica Therapeutics Inc. announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12, 2019, at the Sheraton New York Times Square Hotel in New York City.
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
The company provides a corporate update. in the letter.
DiaMedica today announced that at its Annual General and Special Meeting of shareholders held on December 21, 2017.
The proceeds will be used by the Company to support development with DM199 for the treatment of stroke and for other working capital purposes.
The Offering is being offered on a non-brokered private placement basis to accredited investors.
DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase II Trial for Acute Ischemic Stroke
REMEDY is a multi-center, double-blind, randomized, placebo-controlled Phase 2 clinical trial investigating DM199 treatment in patients who have suffered a moderate to moderately severe acute ischemic stroke.
Any warrants not exercised prior to the accelerated expiry date and time will expire without any further action being taken.
DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
The study was designed to compare the profile of DM199 to that of the approved urinary KLK1 product (trade name Kailikang) on the market in Asia for acute ischemic stroke.